2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ghosh PM et al. | Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. | 1999 | Oncogene | pmid:10435593 |
Aizman E et al. | Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. | 2012 | Oncotarget | pmid:22323550 |
Mashiach-Farkash E et al. | Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. | 2012 | Oncotarget | pmid:22776759 |
Schmukler E et al. | Ras inhibition enhances autophagy, which partially protects cells from death. | 2013 | Oncotarget | pmid:23847721 |
Schmukler E et al. | Ras inhibition enhances autophagy, which partially protects cells from death. | 2013 | Oncotarget | pmid:23370967 |
Barkan B et al. | Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. | 2013 | Oncotarget | pmid:23530091 |
Faigenbaum R et al. | Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. | 2013 | Oncotarget | pmid:23530112 |
Hameiri-Grossman M et al. | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | 2015 | Oncotarget | pmid:26393682 |
Goldshmit Y et al. | Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. | 2014 | Oncotarget | pmid:25261371 |
Schmukler E et al. | Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death. | 2014 | Oncotarget | pmid:24368422 |